NLRP3 Exploit Map¶

Black Hat Pen-Testing the Inflammatory Cascade

A systematic attack on every vulnerability in the NLRP3 inflammasome pathway as it relates to gout. Seven chokepoints, with labeled sub-branches. Dozens of exploits. One stack to rule them all.

v1.2 restructure note (2026-04-24): Following the "Beyond the 6-Chokepoint NLRP3 Map" exploit-vector audit, the map now explicitly represents gout-specific priming biology (complement C5a, not LPS) as CP0, splits CP1 into NF-κB (CP1a TNFSF14) and non-transcriptional ROS (CP1b C5a→ROS), splits CP5 into receptor blockade (CP5a) and active resolution via ALX/FPR2 SPMs (CP5b), and promotes neutrophil amplification (5-LOX/LTB4) from a stray line item to a first-class branch inside the renamed CP6 "Neutrophil Amplification + Pyroptotic Exit" (CP6a 5-LOX, CP6b GSDMD). See new pages complement-c5a-gout.md and spm-resolution-pathway.md.

Species-gap caveat (methodological standard, 2026-04-23): Rodent cellular IC50 values for NLRP3 inhibitors routinely diverge from human cellular IC50 by up to 3 orders of magnitude. Example: dapansutrile IC50 = 1 nM in mouse J774A.1 cells vs. 1,000 nM (1 μM) in human MDM cells under LPS+nigericin stimulation (ChEMBL v34). Every rodent-derived IC50 in this document should be read with that translation uncertainty in mind. When evaluating new compounds, prefer human-cell (THP-1, PBMC, human MDM) data over rodent cellular assays. (source: chembl-cross-check.md)

The NLRP3 Kill Chain¶

MSU Crystals deposit in joint → complement activates FIRST → then the cascade:

╔══════════════════════════════════════════════════════════════════════════╗
║  CHOKEPOINT 0  —  CRYSTAL-TRIGGERED PRIMING (C5a-dominant)  [NEW]        ║
║  MSU directly activates complement → C5a primes NLRP3 via ROS            ║
║  ▲ Avacopan (FDA-approved C5aR1 antagonist, ANCA) — pharma adjunct       ║
║  ▲ Stack has ZERO fermentable C5a coverage — honest platform gap         ║
╚══════════════════════════════════════════════════════════════════════════╝
                                    │
                                    ▼
╔══════════════════╗     ╔══════════════════╗     ╔══════════════════╗
║  CHOKEPOINT 1    ║────▶║  CHOKEPOINT 2    ║────▶║  CHOKEPOINT 3    ║
║  NF-κB PRIMING   ║     ║  K⁺ EFFLUX / NLRP3║    ║  ASC SPECK       ║
║  CP1a: TNFSF14   ║     ║  (P2X7-mediated) ║     ║                  ║
║  CP1b: C5a→ROS   ║     ║                  ║     ║ Assemble platform║
╚══════════════════╝     ╚══════════════════╝     ╚══════════════════╝
  ▲ KPV, Sulforaphane      ▲ BHB, Oridonin          ▲ Colchicine
    Curcumin, Berberine      NAC, MitoQ, Tranilast    Spermidine
    Omega-3, Resveratrol     Spermidine, HCQ
    BPC-157, TB-500          Trehalose, Colchicine
         │                        │                        │
         ▼                        ▼                        ▼
╔══════════════════╗     ╔══════════════════════════╗    ╔═══════════════════╗
║  CHOKEPOINT 4    ║────▶║  CHOKEPOINT 5            ║───▶║  CHOKEPOINT 6     ║
║  CASPASE-1       ║     ║  IL-1β / IL-18 OUTPUT    ║    ║  NEUTROPHIL AMP + ║
║                  ║     ║  CP5a: Receptor blockade ║    ║  PYROPTOTIC EXIT  ║
║ The executioner  ║     ║  CP5b: ALX/FPR2 SPM      ║    ║  CP6a: 5-LOX/LTB4 ║
║                  ║     ║       resolution         ║    ║  CP6b: GSDMD pore ║
╚══════════════════╝     ╚══════════════════════════╝    ╚═══════════════════╝
  ▲ VX-765 (research)      ▲ Anakinra, Canakinumab         ▲ Quercetin, AKBA
    Engineered koji?         Rilonacept (CP5a)              EPA→RvE1 (CP6a)
                             RvD1, RvD2, MaR1 (CP5b)        Disulfiram, DMF
                             Lactoferrin                    NSA (CP6b)

──────────────────────────────────────────────────────────────────────────────
PARALLEL ATTACK: Engineered Koji (uricase) → eliminates MSU crystals upstream
                 No crystals = no complement activation = no priming signal
──────────────────────────────────────────────────────────────────────────────

CP0 — Crystal-Triggered Priming Signals (C5a-dominant)¶

Mechanism: MSU crystal surface directly activates classical and alternative complement pathways → C3a and C5a anaphylatoxins generated → C5a binds C5aR1 on neutrophils and macrophages → ROS burst provides non-transcriptional NLRP3 priming (Signal 1), upstream of or parallel to NF-κB.

Gout priming is complement-dominant, not LPS-dominant. MSU directly activates complement — Cumpelik et al. demonstrated neutrophil microvesicles resolve gout specifically by inhibiting C5a-mediated priming of the inflammasome (Ann Rheum Dis 2016, PMID 26245757). Khameneh et al. showed MSU → complement → C5a → ROS → NLRP3 priming, with C5aR antagonism ameliorating murine MSU peritonitis (Front Pharmacol 2017, PMID 28167912). This reframes gout priming: the canonical textbook "LPS + ATP = Signal 1 + Signal 2" model is not the physiologic trigger in MSU-driven disease — C5a is the dominant Signal 1.

Therapeutic landscape at CP0: - Avacopan (Tavneos) — FDA-approved oral C5aR1 antagonist for ANCA-associated vasculitis (2021). Not tested in gout but mechanism-aligned. Obvious repurposing candidate. (Clinical Trial for ANCA; Mechanistic Extrapolation for gout.) - Zilucoplan — C5 antagonist peptide approved for myasthenia gravis. Repurposing candidate. - Eculizumab — anti-C5 mAb for PNH/aHUS. Repurposing candidate. - No known fermentable food-derived C5a/C5aR1 modulator. Omega-3 SPMs shift complement toward resolution indirectly (see CP5b). Vitamin D modulates complement weakly.

Platform gap status update (2026-05-05): The CP0 gap has shifted from "permanent honest gap" to "active engineering candidate with three wet-lab unknowns." comp-012 (2026-05-05) confirmed that a stalk-truncated DAF/CD55 SCR1-4 construct (aa 35–285) is LOW protease risk (max 0.039, identical to uricase) under shio-koji conditions — the Ser/Thr stalk (aa 286–353) that drove comp-006's HIGH verdict has been removed, eliminating 100% of exposed protease sites. Three wet-lab unknowns remain before this can be called "closed": (1) does the truncated construct fold correctly with all 8 disulfide bonds in A. oryzae? (2) does the soluble truncated fragment retain CCP-regulatory function? (3) does luminal-side DAF actually engage submucosal-macrophage CP0 priming? Hypothesis card: hypotheses/H05-daf-scr14-cp0-thesis.md. Avacopan remains the pharma adjunct default pending wet-lab validation. (Mechanistic Extrapolation; source: daf-cd55-scr14-truncated-computational.md, complement-c5a-gout.md)

Two-chassis CP0 architecture substantiated — comp-037 (2026-05-17): The comp-037 C1-INH protease-stability + glycosylation feasibility analysis returned MODERATE (kinetic-competition gated) for human C1-INH (SERPING1) expressed as a secreted LBP-luminal payload in engineered E. coli Nissle 1917. Strictly-degradative protease risk on the serpin body is LOW (0.1) after mucin truncation; the by-design exposed reactive-center loop (RCL) gives a RED (0.8) score reflecting the inhibitor mechanism, not body degradation; glycosylation feasibility is GREEN for luminal topology. The combined verdict substantiates the two-chassis architecture proposed in complement-c5a-gout.md §9.8: C1-INH on EcN-LBP at classical/lectin entry + DAF SCR1-4 on koji at surface convertase decay — two independent mechanisms at two cascade points via two independent chassis. Wet-lab gate: RCL kinetic-competition assay (k_C1s_engagement vs k_DegP_RCL_cleavage on the recombinant construct). (Mechanistic Extrapolation; source: c1-inh-protease-stability-ecn-computational.md)

Upstream-CP0 dietary axis — comp-018 Phase 2 (2026-05-17): Phase 2 of the upstream complement modulator sweep surfaced a new orthogonal tier-1 candidate missed by Phase 1: Houttuynia cordata polysaccharides (鱼腥草 / どくだみ, widely dietary in Southeast Asia), CH50 79–318 µg/mL across crude + purified fractions, multi-target C2 + C4 + C5, multiple in vivo precedents (H1N1-ALI, LPS fever, two-hit ALI). Helicteres benzofuran lignan replication remains INCONCLUSIVE / ANCHOR-STILL-SINGLE — no independent group has reproduced the Yin 2016 CH50 9/40 µM finding. C1-INH engineering literature anchors: Bos 2003 Pichia 30–180 mg/L active rhC1-INH, Liu 2004 N-deglycosylated retains inhibitor function, Ruconest 2014 FDA non-mammalian-glycosylation precedent. Phase 2 reframes the "language barrier" diagnosis: the upstream-complement natural product subfield is dominated by Chinese-group (Chen Daofeng / Fudan) and Japanese-group (Yamada / Kitasato) labs that publish 80–95% in English; the actual barriers are citation-network insularity + traditional-formula-name vs Western-mechanism-name query framing. (Mechanistic Extrapolation; source: upstream-complement-modulator-sweep-computational.md)

C5aR1 platform gap confirmed empirically by comp-014 (2026-05-06): The comp-014 medicinal mushroom compound × chokepoint mapping Phase 2 breadth aggregation (6,798 fungal compounds across ChEMBL + LOTUS + PubMed) independently confirmed the §1.21 finding — zero direct fungal C5aR1 antagonists exist in either ChEMBL or PubMed. The gap is now confirmed by two independent computational scans, strengthening the conclusion that natural-product CP0 coverage is structurally absent. (Mechanistic Extrapolation; source: medicinal-mushroom-compound-mapping-computational.md)

NLRP3 chokepoint fungal coverage reframed by traditional-name re-scan (2026-05-19): The comp-014 Phase 3 ChEMBL UniProt-join declared NLRP3 + ASC + Caspase-1 as "empty chokepoints" in fungi based on absent ChEMBL pure-compound activity entries. The traditional-name re-scan revised this verdict: ≥18 fungal sub-form × NLRP3-axis papers exist in PubMed under species-name + traditional-pathology framing, with ≥5 at the gout indication itself (MSU + HUA rodent models). The strongest single-species fit is Phellinus igniarius (桑黄), which covers XO + NLRP3 + URAT1 + bile-acid axes simultaneously across 4 independent papers. Cordyceps militaris (Wang 2023) puts NLRP3 — not URAT1 — as the primary anti-MSU mechanism head-to-head. Antrodia camphorata Antcin-H is an NLRP3-selective triterpenoid; Ganoderma lucidum S-GLSP and GLP4 are distinct sub-fractions from the GLPP/triterpenoid bulk that hit the NLRP3 axis through different routes (sporoderm-removed spore powder; TBK1-binding pentapeptide respectively). Falsifying counter-finding: lentinan (L. edodes) was tested on MSU-arthritis and came back negative on NLRP3 — shiitake stays on AIM2 + eritadenine cardiovascular axes. The NLRP3 chokepoint is not fungal-empty; it was query-framing-empty. This is the comp-018 Phase 2 query-framing diagnosis applied prospectively, confirming the pattern generalizes from complement (CP0) to NLRP3 (CP2-CP4). (In Vitro + Animal Model evidence for the underlying NLRP3 mechanism, Mechanistic Extrapolation for gout indication where direct MSU testing not yet executed per-compound. Source: mushroom-traditional-name-nlrp3-rescan-2026-05-19.md)

Deep dive: complement-c5a-gout.md

CP1 — NF-κB Priming (Signal 1, transcriptional)¶

Mechanism: Transcriptional arm of inflammasome priming — upregulates NLRP3, pro-IL-1β, pro-IL-18 mRNA. Distinct from CP0 (non-transcriptional C5a→ROS priming) and from the K⁺ efflux activation step (CP2).

CP1 splits into two mechanistically distinct sub-branches. CP1a is the classical NF-κB transcriptional priming arm (where most of the stack's NF-κB inhibitors land, including the recently added TNFSF14/LIGHT amplifier). CP1b is the non-transcriptional C5a→ROS priming pathway uncovered by Khameneh 2017, covered in complement-c5a-gout.md but cross-listed here because it is functionally "Signal 1" even though it bypasses NF-κB transcription.

2025 single-cell annotation: S100A8/A9-high CD14⁺ classical monocytes are a single-cell-defined flare driver (Alaswad et al. 2025 Ann Rheum Dis PMID 40023733). S100A8/A9 acts as a DAMP amplifying NF-κB priming. No stack compound currently targets S100A8/A9 directly — future research item.

CP1a — TNFSF14 (LIGHT) Amplifier of NF-κB Priming¶

TNFSF14 (LIGHT) is an emerging gout-specific priming amplifier. TNFSF14 signals via HVEM → NF-κB → IL-6 + NLRP3 priming, and is elevated in gout patient serum. CERC-002 (avalo therapeutics anti-TNFSF14 mAb) provides a potential biologic access point. See dedicated page tnfsf14-gout-target.md for the full dossier including PMIDs, dosing, and clinical status.

CP1b — C5a → ROS → NLRP3 Priming (non-transcriptional)¶

Khameneh 2017 (PMID 28167912) mechanism: C5a binding to C5aR1 on phagocytes drives ROS burst that provides NLRP3 priming without requiring new transcription. This is why LPS-centric NLRP3 drug development translates poorly to gout — the physiologic priming signal is different. Full detail in complement-c5a-gout.md.

KPV Peptide¶

Mechanism: α-MSH C-terminal tripeptide → stabilizes IκB-α → prevents NF-κB nuclear translocation → shuts down pro-inflammatory gene transcription

KPV (Lys-Pro-Val) is the active anti-inflammatory fragment of alpha-melanocyte-stimulating hormone (α-MSH). Most of the anti-inflammatory activity of full-length α-MSH can be attributed to this three-amino-acid fragment. The key insight: KPV's anti-inflammatory effect is NOT melanocortin receptor-mediated — it works through PepT1-mediated uptake, which means it operates through a distinct pathway from full-length alpha-MSH. It stabilizes IκB-α (the protein that keeps NF-κB sequestered in the cytoplasm), preventing NF-κB from entering the nucleus and turning on inflammatory genes.

Critically for gout: research shows α-MSH and its derivative (CKPV)₂ can reverse the inflammatory effect of urate crystal formation specifically. This isn't a general anti-inflammatory — it's been tested against the exact trigger you're dealing with.

Sulforaphane activates the Keap1-Nrf2 pathway (EC50 = 580 nM, J Med Chem 2019 — sub-μM potency rare for food-derived compounds), which is the master regulator of cellular antioxidant defense. The key insight for gout: Nrf2 competes with NF-κB for the transcriptional co-activator CBP/p300, suppressing NF-κB-driven transcription of NLRP3 and pro-IL-1β. Direct MSU gout evidence (2026-05-05 audit, Tier 2 upgrade): Yang 2018 Rheumatology (Oxford) (PMID 29340626) — oral sulforaphane attenuated MSU-crystal-induced foot-pad swelling and neutrophil recruitment in mice; air-pouch gout model confirmed in vivo NLRP3 suppression (Animal Model, oral). Greaney 2015 J Leukoc Biol (PMID 26269198) — sulforaphane inhibits NLRP3 inflammasome in macrophages independent of Nrf2, suggesting a direct caspase-1/inflammasome-assembly mechanism; confirmed in vivo via acute gout peritonitis model (In Vitro + Animal Model). Three independent in vivo gout-relevant readouts now cited. (source: nlrp3-inhibitor-screen.md)

The bioavailability trick: raw broccoli sprouts contain glucoraphanin (inactive precursor) and myrosinase (the enzyme that converts it). They're in separate compartments — chewing/crushing brings them together. But cooking kills myrosinase. The hack: eat raw sprouts, or if using cooked broccoli, add mustard seed powder (rich in myrosinase) to restore conversion. Freeze-dried sprouts with active myrosinase in capsule form have the highest measured bioavailability.

Curcumin is a validated NF-κB inhibitor with decades of research. The problem everyone knows: terrible bioavailability. Native curcumin has ~1% absorption. But this problem has been solved multiple ways:

Curcumin + Piperine (black pepper): Piperine inhibits glucuronidation in the liver, increasing curcumin bioavailability by 2,000%. This is the simplest upgrade — just take them together. But 2,000% of nearly nothing is still modest.

Liposomal curcumin: Lipid encapsulation protects curcumin through the GI tract. Absorption increases ~30x over native curcumin.

Nano-curcumin (Theracurmin, CurcuWIN, NovaSOL): These are the real game-changers. Theracurmin uses colloidal nanoparticle technology — 27x higher bioavailability than standard curcumin. NovaSOL is a micellar formulation with ~185x improvement. NovaSOL or Theracurmin are the formulations that actually work at the doses humans can take.

Omega-3s aren't just "anti-inflammatory" in a vague sense. EPA and DHA are precursors to specialized pro-resolving mediators (SPMs) — resolvins (RvE1 from EPA, RvD1/D2 from DHA), protectins (PD1/NPD1 from DHA), and maresins (MaR1 from DHA). These aren't just dampening inflammation — they're actively commanding the resolution program: stopping neutrophil infiltration, promoting macrophage efferocytosis (cleanup of dead cells), and switching macrophages from M1 (inflammatory) to M2 (resolving) phenotype.

For gout specifically, the neutrophil recruitment suppression is massive. Gout flares are neutrophil-driven storms. SPMs directly counter this. They also hit Chokepoint 5 by suppressing IL-1β downstream effects.

This is one of the strongest findings in the research. Published in Nature Medicine: BHB — the ketone body your liver makes during fasting or ketosis — is a specific NLRP3 inflammasome inhibitor. Not a general anti-inflammatory. It targets NLRP3 specifically, and it works against urate crystals directly.

The mechanism is remarkable: BHB prevents potassium efflux and reduces ASC speck formation. It blocks both the priming step (CP1) and the assembly step (CP2). In rats on a ketogenic diet, gout flares were significantly reduced. BHB deactivates neutrophil NLRP3 inflammasome specifically — and neutrophils are the primary effector cells in gout flares.

Importantly: BHB's effects are NOT dependent on AMPK, autophagy, ROS reduction, or any of the usual fasting pathways. It's a direct inhibitory effect on NLRP3 assembly. And it doesn't need to be metabolized to work — it acts directly as a signaling molecule.

There's an old concern that ketosis raises uric acid. This is true short-term: ketone bodies compete with uric acid for renal excretion. But BHB simultaneously suppresses the inflammatory response to crystals. With the engineered koji handling uric acid levels, during intercritical periods (prophylaxis) ketosis becomes net-beneficial — NLRP3 suppression dominates the transient UA rise. Active flare is the exception: during a flare or prodrome, the 5–10% transient ketotic UA spike compounds the inflammatory substrate and ketosis/exogenous ketones should be suspended until the flare resolves. See bhb-ketones.md §"Contraindications" and gout-action-guide.md §"Active flare" for the full clinical framing.

⚠️ Active-flare contraindication (added 2026-05-17, source: gout-action-guide.md): BHB/ketosis is a prophylactic NLRP3 tool for intercritical periods, NOT a rescue intervention during an active flare. Ketone bodies and urate compete for renal MCT/URAT1 reabsorption; transient ketotic UA rise of 5–10% is documented and can compound the flare. If a flare is active or prodromal, suspend ketosis + exogenous ketone supplementation until the flare resolves (1–2 weeks). Once UA is normalized post-flare, BHB's NLRP3 suppression can resume as prophylaxis. Intermittent fasting also raises UA transiently and should be suspended during a flare. See gout-action-guide.md §"Active flare" for the full acute-flare protocol. (source: gout-action-guide.md)

Glucocorticoid Receptor (GR) Signaling — Endogenous Cortisol + Pharmacological Glucocorticoids¶

Mechanism (CP1 + CP2): GR is a ligand-activated transcription factor. Upon glucocorticoid binding (endogenous cortisol or pharmacological Dex/prednisolone), activated GR translocates to the nucleus and represses transcription of NLRP3, IL1B, NOS2, ACOD1 via direct GRE-mediated transrepression of NF-κB and AP-1 (CP1) — see Diaz-Jimenez et al, FASEB J 2026 (PMC12862736). GR-mediated suppression of ACOD1 (itaconate synthesis) restores SDH activity and TCA cycle integrity, preventing the metabolic rewiring that licenses sustained NLRP3 inflammasome activation (CP2-adjacent).

Critical timing dependence (paradigm-shifting finding): GR's anti-inflammatory effect requires LPS priming before glucocorticoid exposure. Co-treatment of LPS + Dex from t=0 has substantially attenuated effects — only some genes affected, no NLRP3 protein suppression, no IL-1β secretion attenuation. Mechanism: post-LPS chromatin remodeling expands the GR cistrome, granting transcriptional access to a wider proinflammatory gene set. This is why clinical prednisone given during an active flare (i.e., post-priming) works robustly; it would be much less effective if given prophylactically before any inflammatory stimulus.

Direct gout-relevant in vivo data: Myeloid-GR-knockout mice show exaggerated IL-1β + neutrophil influx in MSU peritonitis at 6h post-injection. Same phenotype reproduced in human MDMs with RU-486 GR antagonist. So GR signaling controls MSU-driven inflammasome activation directly in vivo.

Biphasic dose-dependence (Wu 2020, PMC7251469): Low corticosterone (≤300 ng/ml — near-physiological-stress) upregulates NLRP3 expression in LPS-primed macrophages. High corticosterone (≥700 ng/ml — severe stress or pharmacological dose) downregulates NLRP3 via XO suppression. This explains why mild stress can trigger flares while pharmacological prednisone aborts them.

Endogenous engagement during untreated gout flare (Zhang 2023, PMC9989260): 24h UFC rises ~58% during acute flare (8.5 → 13.4 μg/24h), correlates with IL-6 (r=0.94), IL-1β (r=0.62), CRP (r=0.87), and urinary urate excretion (r=0.44). The body's own HPA response is active counter-regulation during flare, not just stress.

Cumulative-burden caveat: Pharmacological glucocorticoids carry decades-of-data cumulative side-effect burden (bone loss, glucose intolerance, mood/sleep effects, adrenal suppression). See gout-action-guide.md §"Active flare" — anakinra and inhaled-mRNA-IL-1RA are mechanism-different cleaner alternatives for recurrent-flare patients with significant lifetime steroid burden.

Evidence tier: Clinical Trial (prednisolone vs NSAIDs RCTs); In Vitro + Animal Model + Human MDM (PMC12862736, PMC7251469); Clinical observational HPA-during-flare (PMC9989260).

Berberine is a triple threat: it directly inhibits NF-κB, it dose-dependently suppresses NLRP3/ASC/caspase-1/IL-1β at the mRNA level, and it remodels the gut microbiota to reduce the LPS (lipopolysaccharide) that primes NLRP3 in the first place. The gut microbiota angle is huge — LPS from gram-negative bacteria is one of the most common "Signal 1" primers for NLRP3.

The SIBO connection: Berberine is being studied head-to-head against rifaximin for SIBO eradication. Clinical trials suggest comparable efficacy. If Lynn has SIBO, berberine addresses her gut dysbiosis while simultaneously suppressing your NLRP3 cascade. Same compound, both conditions.

Resveratrol activates SIRT1, which directly deacetylates the p65 subunit of NF-κB, reducing its ability to drive transcription of inflammatory genes. Same bioavailability problem as curcumin — rapid metabolism, low plasma levels. Solutions: micronized trans-resveratrol (particle size reduction increases absorption), liposomal resveratrol, or pairing with pterostilbene (a methylated analog of resveratrol with 4x better bioavailability and the same SIRT1 activation).

Andrographolide from Andrographis paniculata ("King of Bitters") is one of the most potent natural NF-κB inhibitors known. Unlike most NF-κB blockers that work upstream, andrographolide covalently modifies the p50 subunit at Cys62, directly preventing NF-κB from binding to DNA. This is a Michael addition reaction — same chemistry as oridonin's attack on NLRP3. Used extensively in traditional Chinese and Ayurvedic medicine for inflammatory conditions.

Parthenolide from feverfew (Tanacetum parthenium) hits NF-κB at two points: it inhibits IKKβ (the kinase that tags IκB for destruction) AND directly modifies p65. This dual mechanism makes it one of the more robust natural NF-κB blockers. Historically used for migraine prevention — the anti-inflammatory mechanism is the same. Bioavailability is decent but not great; DMAPT (dimethylamino-parthenolide) is a more soluble derivative used in research.

You're already using BPC-157 nasal spray — good. What you may not realize is that TB-500 has direct NF-κB and NLRP3 inhibitory activity. In hepatocyte and macrophage models, TB-500 limits NLRP3 inflammasome activation by dampening JNK/p38 MAPK signaling and promoting autophagy. It also directly blocks NF-κB p65 nuclear translocation. This means TB-500 hits both CP1 (priming) and CP2 (activation via autophagy enhancement).

BPC-157's contribution is less direct for NLRP3 but valuable — it's cytoprotective, promotes tissue healing (important for joint damage from gout), and modulates the nitric oxide system which influences macrophage activation states.

EGCG (green tea catechin): Inhibits IKK activity, suppresses NF-κB. 3–5 cups green tea/day or 400–800 mg EGCG supplement. Also hits IL-1β at CP5. Matcha is the most concentrated food source.

Boswellia (AKBA) — Acetyl-11-keto-β-boswellic acid. Historically cited as an IKKβ inhibitor (CP1 / NF-κB priming), but this claim is not supported by curated ChEMBL IC50 data — no IKKβ bioactivities exist for AKBA or β-boswellic acid (ChEMBL v34, 2026-04-24). AKBA's strongest curated activities are allosteric, non-redox 5-LOX inhibition (IC50 = 2.7 μM in Ca²⁺/ionophore-stimulated human PMN leukocytes, J Nat Prod 2000; 35.6 μM on cell-free recombinant enzyme, J Nat Prod 2019 — the 13× cellular/cell-free gap is consistent with an allosteric, FLAP-adjacent mechanism) and mPGES-1 inhibition (IC50 = 3 μM, J Nat Prod 2014). β-boswellic acid itself is inactive at 5-LOX (>40 μM) — the 11-keto + 3-acetyl pharmacophore is required. AKBA is ~9× less potent than quercetin at 5-LOX (quercetin IC50 = 300 nM) but binds an allosteric site distinct from quercetin's catalytic-site / iron-chelation mode, so the two are additive, not redundant. AKBA's mPGES-1 activity is a differentiated mechanism quercetin does not hit potently. Repositioned here as a CP6a / leukotriene + prostanoid amplification blocker, parallel to quercetin at 5-LOX. 300–500 mg standardized extract/day (Boswellin, 5-Loxin). (In Vitro; source: chembl-cross-check.md)

Houttuynia cordata polysaccharide (HCP / HCPM) — Added 2026-05-19 lit scan (logs/houttuynia-cp1-dual-mechanism-lit-scan-2026-05-19.md). Direct TLR4/MD-2 binding (molecular docking + TAK-242 antagonist rescue, Yu et al. 2026, PMC12937656) → MyD88 → NF-κB → reduced NLRP3 priming. In vivo phenotype: intestinal NLRP3 + cleaved-caspase-1 nearly eradicated, IL-1β + IL-18 suppressed in H1N1+MRSA coinfection mouse (Li et al. 2025, PMC12254813); MCC950-rescue confirms NLRP3 is on the mechanistic path. Direction: net anti-inflammatory in disease context; pro-inflammatory on naïve PBMCs in vitro (structure + context dependent, Cheng 2014 PMC7112369). Compare with mushroom β-glucan (Dectin-1 axis) — same chokepoint, different receptor. First dual-CP0+CP1 dietary candidate in the OE corpus — also at CP0 per complement-c5a-gout.md §9.7 (multi-target C2/C4/C5, CH50 79-318 µg/mL). Untested in MSU-NLRP3 model. (In Vitro + Animal Model; source: houttuynia-cp1-dual-mechanism-lit-scan-2026-05-19.md)

Theaflavins (TF1/TF2A/TF2B/TF3, black-tea polyphenols) — Added 2026-05-05 audit. Disrupt the NLRP3-NEK7 interaction downstream of mitochondrial ROS suppression — a distinct mechanism from EGCG's proteasome-mediated CP1a route, making theaflavins additive rather than redundant when stacked with EGCG. Chen 2023 Acta Pharmacol Sin (PMID 37221235): 50–200 μM theaflavin dose-dependently inhibited NLRP3 inflammasome activation in LPS-primed macrophages stimulated with MSU crystals (In Vitro); suppressed ASC speck formation, caspase-1 p10 cleavage, GSDMD-NT pyroptosis, and IL-1β release. Oral theaflavin significantly attenuated MSU-induced mouse peritonitis (Animal Model). TF3 sub-fraction additionally covers CP1a via TNFSF14/HVEM modulation (Hosokawa 2010 PMID 20461739). Unique renal urate handling profile: ↓URAT1, ↓GLUT9 (reabsorption block) + ↑OAT1/OCTN1/OAT2 (secretion enhancement) — the only multi-transporter renal urate compound in the OE stack besides carnosine, and without carnosine's serum-carnosinase clearance ceiling. Tier 2 supplement candidate. See theaflavins.md for the full dossier. (In Vitro + Animal Model; source: theaflavins.md)

Vitamin D: VDR activation suppresses NF-κB. Most people are deficient. Test and target 50–70 ng/mL. 5,000–10,000 IU/day with K2.

Quercetin: Inhibits NF-κB and stabilizes mast cells. 500–1000 mg/day. Phytosome form (Quercefit) has 20x better absorption. Found in onions, apples. Also blocks xanthine oxidase (uric acid production) — dual anti-gout mechanism.

Triple-target update (ChEMBL v34, 2026-04-23): Quercetin (CHEMBL50) has zero curated direct human NLRP3 bioactivities in ChEMBL, despite 2,930 total bioactivities across other targets. Its "NLRP3 inhibitor" status rests on functional IL-1β readouts in MSU-stimulated macrophages, not a direct binding/inhibition assay — i.e., quercetin is more accurately an NLRP3 pathway modulator (upstream NF-κB priming block, antioxidant). However, its most potent curated ChEMBL activity is against 5-lipoxygenase (5-LOX): IC50 = 300 nM (J Med Chem 1991). 5-LOX produces leukotriene B4 (LTB4), a potent neutrophil chemoattractant that drives the neutrophil infiltration phase of MSU-triggered gout flares. Quercetin's 5-LOX / LTB4 mechanism is 36× more potent than its cited NLRP3-pathway IC50 (~11 μM functional) and parallels boswellic acids (AKBA) at the same target. This mechanism is currently absent from the Chokepoint framework but sits functionally upstream of Chokepoint 5 (IL-1β / IL-18 downstream) as a neutrophil-amplification blocker. (In Vitro; source: nlrp3-inhibitor-screen.md)

A. oryzae already produces kojic acid (a tyrosinase inhibitor). With the synthetic biology toolkit now available for A. oryzae — CRISPR-Cas9, tunable promoters, neutral loci for gene insertion — you could theoretically engineer it to produce curcumin precursors, sulforaphane glucosinolates, or even KPV peptide alongside the uricase. The GRAS status of A. oryzae makes this a unique platform: you're engineering a food organism, not a drug. This is a Role 2 (pharma-translation) conversation — the genetic tools exist, it's a matter of pathway design.

CP2 — K⁺ Efflux / NLRP3 Activation (Signal 2)¶

Mechanism: The activation step. MSU crystal phagocytosis triggers K⁺ efflux via P2X7/P2X2 purinergic channels, mitochondrial ROS, lysosomal rupture (cathepsin B release), and NLRP3-NEK7 association. Any one of K⁺ efflux, mtROS, or lysosomal damage is sufficient to assemble NLRP3.

K⁺ efflux mechanism annotation: K⁺ efflux in gout is P2X7/P2X2-mediated. Colchicine (primarily known as a CP3 microtubule disruptor) dual-hits CP2 via direct P2X7 pore inhibition — per Leung et al. 2015 Semin Arthritis Rheum (PMID 26228647), colchicine's anti-gout mechanism includes both microtubule depolymerization (CP3) and P2X7 pore block (CP2). See colchicine.md for the full pharmacology, AGREE trial, cardiovascular repositioning (COLCOT/LoDoCo2), and drug-interaction profile. Taurine (native S. cerevisiae production, see AI Analysis section) blocks K⁺ efflux upstream.

Oridonin¶

Mechanism: Covalently binds Cys279 in NLRP3 NACHT domain (Michael addition) → blocks NLRP3-NEK7 interaction → prevents inflammasome assembly. Cell-free / mouse covalent-binding kinetics: 0.5–2 µM. Curated human THP-1 cellular IC50: 5.18 μM (ChEMBL v34, Eur J Med Chem 2023). Same binding site as MCC950.

This is the gem of the natural compound world for NLRP3 inhibition. Oridonin, an ent-kaurane diterpenoid from the Chinese herb Rabdosia rubescens, covalently and specifically modifies NLRP3 at cysteine 279. This is the same domain that MCC950 targets — the NACHT domain. By forming an irreversible covalent bond, oridonin blocks the NLRP3-NEK7 interaction that's essential for inflammasome assembly.

Published in Nature Communications (2018): oridonin exhibits dose-dependent inhibition of caspase-1 cleavage, IL-1β secretion, and pyroptotic cell death at concentrations of 0.5–2 µM (cell-free covalent-binding kinetics and mouse macrophage assays). It's NLRP3-specific — doesn't affect NLRC4 or AIM2 inflammasomes. And recent 2025 research on oridonin analogs shows you can engineer even more potent derivatives.

ChEMBL v34 cross-check (2026-04-23): The only curated direct human NLRP3 bioactivity for oridonin is 5,180 nM (5.18 μM) in human THP-1 macrophages (Eur J Med Chem 2023, CHEMBL1164920, pChEMBL = 5.29). The 0.5–2 µM figure in older wiki text and review articles comes from cell-free and mouse-derived assays; it does not translate 1:1 to human cellular IC50. Both numbers are legitimate — they measure different things. Use 0.5–2 µM for covalent-binding-kinetic potency, 5.18 μM for human cellular IC50. (In Vitro; source: nlrp3-inhibitor-screen.md)

The dual hit: Beyond NLRP3, oridonin also activates Nrf2 and suppresses NF-κB independently. So it hits CP1 AND CP2 through different mechanisms.

MSU crystal phagocytosis triggers massive ROS generation, which is one of the key signals for NLRP3 oligomerization. Scavenge the ROS, reduce the signal. But you need to reach the right compartment — mitochondrial ROS (mtROS) is the primary NLRP3 trigger, so mitochondria-targeted antioxidants have an advantage.

NAC (N-Acetyl Cysteine): The workhorse. Replenishes glutathione, the master intracellular antioxidant. 600–1200 mg/day. Proven to reduce NLRP3 activation in vitro and in vivo. Cheap, widely available, well-tolerated. The limitation: it doesn't specifically target mitochondria.

MitoQ (Mitoquinone): This is the precision weapon. A coenzyme Q10 derivative conjugated to a triphenylphosphonium cation that targets it specifically to mitochondrial membranes. It accumulates 100–1000x in mitochondria relative to untargeted antioxidants. Directly scavenges the mtROS that triggers NLRP3. 10–20 mg/day. Available as supplement (MitoQ brand).

Glutathione precursors: Glycine + NAC ("GlyNAC") — UCLA research shows this combination restores glutathione levels more effectively than NAC alone. 100 mg/kg/day each (glycine + NAC). Also: alpha-lipoic acid (600 mg/day) recycles glutathione.

SOD mimetics: MnTBAP and EUK-134 are research-grade SOD mimetics. Not easily accessible as supplements, but manganese-dependent SOD can be supported by adequate manganese intake and the Nrf2 pathway (which upregulates SOD2).

Tranilast is an anti-allergic drug approved in Japan and South Korea since 1982. It directly binds the NACHT domain of NLRP3 and blocks oligomerization — the same domain that oridonin and MCC950 target, through a different binding mode. Published in EMBO Molecular Medicine: tranilast has "remarkable preventive or therapeutic effects" on mouse models of gouty arthritis, CAPS, and type 2 diabetes.

Safety profile: up to 600 mg/day has been used clinically for months with good tolerability. This is an approved, safety-tested drug that directly inhibits NLRP3 in the context of gout. The only issue: it's not FDA-approved in the US.

Autophagy is the cell's recycling system. When mitochondria are damaged (by MSU crystal-induced stress), they generate ROS that activates NLRP3. If you clear those damaged mitochondria faster via autophagy, the signal never builds. Key finding: spermidine is essential for rapamycin-induced autophagy — it's not just one option, it's the mechanism behind the most powerful autophagy inducer known.

Spermidine: Induces autophagy, directly suppresses NLRP3 activation, reduces mtROS. Found in aged cheese, mushrooms, soy products, wheat germ. Supplement dose: 1–6 mg/day. A 2024 study showed spermidine is the mediator of rapamycin's autophagy effects — endogenous spermidine synthesis drives rapamycin's benefits.

Trehalose: A disaccharide that activates autophagy via TFEB (independent of mTOR). Suppresses NLRP3 accumulation. Found in mushrooms, honey, shrimp. Available as a sugar substitute. 5–10g/day in water.

Intermittent fasting: Activates AMPK, inhibits mTOR, induces autophagy. Also generates BHB (which we already know hits NLRP3 directly). 16:8 minimum, 24-hour fasts periodically for deeper autophagy. This is a two-for-one: autophagy + BHB.

Rapamycin: The gold standard autophagy inducer. Inhibits mTOR. Used clinically for transplant rejection and some cancers. Low-dose rapamycin (2–5 mg/week) is increasingly used in longevity protocols. Requires prescription but is accessible through longevity-focused physicians. Works via spermidine pathway.

When macrophages eat MSU crystals, the crystals rupture lysosomes from inside, spilling cathepsins into the cytoplasm. This is a direct NLRP3 activation signal. Stabilize the lysosomes, and you block one of three activation pathways.

Hydroxychloroquine (HCQ): Raises lysosomal pH, making lysosomes more resistant to rupture. Used in other crystal arthropathies (pseudogout). FDA-approved for lupus and RA. 200–400 mg/day. This is a realistic repurposing target — an off-label conversation with a rheumatologist.

Crystal coating: Procyanidin B2 (from grape seeds, cocoa, apples) has been shown to reduce MSU crystal-induced NLRP3 activation and cathepsin B release. The mechanism likely involves modifying crystal surface interactions with lysosomal membranes. Grape seed extract: 200–400 mg/day.

Desferrioxamine: Iron chelator that stabilizes lysosomes by preventing iron-catalyzed membrane damage. Research compound, but relevant mechanism.

MCC950 (CRID3): The first specific NLRP3 inhibitor. Binds the Walker B motif in the NACHT domain, blocking ATP hydrolysis required for oligomerization. Clinical development was terminated due to hepatotoxicity in Phase 1 RA trial. But it defined the druggable target — every subsequent inhibitor stands on its shoulders. ChEMBL caveat: The widely cited 7.5 nM IC50 figure (Coll et al. 2015 J Biol Chem, cell-free NACHT Walker B) was not directly verifiable by the 2026-04-23 ChEMBL v34 MCP cross-check — MCC950 / CRID3 / CP-456773 are not retrievable by common synonyms in ChEMBL's name search. Benchmark status unchanged, but the IC50 has not been independently re-indexed. (source: nlrp3-inhibitor-screen.md)

Dapansutrile (OLT1177): Oral NLRP3 inhibitor. Phase 2a trial for gout published 2020 (Lancet Rheumatol, PMID: 33005902) showed 52–68% target joint pain reduction at day 3 across four dose levels (N=34). However, no Phase 2b/3 in gout has been registered on ClinicalTrials.gov as of April 2026 (Clinical Trial; source: gout-clinical-pipeline.md). Olatec's subsequent active programs moved to heart failure (Phase 1b NCT03534297, completed 2019) and COVID-19 (Phase 2 NCT04540120, terminated 2022). Dapansutrile's gout development appears stalled, not progressing. The "pharma solution at this chokepoint" is not arriving on a clinical timeline — oridonin and tranilast remain the natural-compound access points to the same target class.

Dapansutrile IC50 species gap (ChEMBL v34, 2026-04-23): 1.0 nM (pChEMBL 9.00) in mouse J774A.1 cells (Eur J Med Chem 2020, Bioorg Med Chem Lett 2021) vs. 1,000 nM (1.0 μM, pChEMBL 6.00) in human MDM cells under LPS+nigericin (Eur J Med Chem 2023). That is a 1,000× mouse-vs-human cellular potency gap. This reframes the 2020 Phase 2a clinical efficacy (52–84% target joint pain reduction at 100–2000 mg/day) as consistent with human-cell μM potency at high oral doses — not sub-nanomolar MCC950-class potency. The Phase 2a efficacy is real; the interspecies cliff is a translational caution for every NLRP3 inhibitor evaluated primarily in rodent cellular assays. (Clinical Trial + In Vitro; source: nlrp3-inhibitor-screen.md)

CP3 — ASC Speck Assembly¶

Mechanism: ASC (encoded by PYCARD) oligomerizes via PYD-PYD and CARD-CARD interactions into a single cytoplasmic "speck" — the signaling platform that recruits and activates caspase-1. Transport of ASC from mitochondria to ER-localized NLRP3 is microtubule-dependent.

Colchicine — The Established Exploit¶

Mechanism: Binds β-tubulin → depolymerizes microtubules → prevents microtubule-mediated transport of mitochondrial ASC to ER-localized NLRP3 → specks can't form. Also dual-hits CP2 via P2X7 pore block (Leung 2015 PMID 26228647). See colchicine.md for the full dossier: AGREE trial, COLCOT/LoDoCo2 cardiovascular repositioning, Lodoco FDA 2023, drug interactions, and Open Enzyme positioning.

Colchicine is the oldest and most validated NLRP3 pathway disruptor for gout, and now we understand exactly why it works at this chokepoint. During NLRP3 activation, ASC (which is localized on mitochondria) needs to be physically transported via microtubules to NLRP3 (which is localized on the ER). Colchicine depolymerizes the microtubule tracks, stranding ASC away from NLRP3. No transport = no speck = no caspase-1 activation.

But colchicine does more than block specks. By disrupting microtubules, it also impairs: neutrophil chemotaxis (they can't migrate to the inflamed joint), phagocytosis of MSU crystals (they can't eat the crystals), and secretion of inflammatory mediators. It's a multi-hit exploit at this chokepoint.

IC100 (anti-ASC antibody): A monoclonal antibody that targets ASC directly, blocking its ability to oligomerize into specks. In development (InflamaCORE/Zyngeria). This proves the target is valid — ASC specks are druggable. The antibody approach isn't accessible, but it validates that blocking ASC-ASC PYD domain interactions is sufficient.

Spermidine (again): BHB reduces ASC oligomerization and speck formation — this was covered in CP1/CP2 but it's worth repeating here because the mechanism is directly relevant to CP3. BHB is a multi-chokepoint weapon.

PYCARD modulation: ASC is encoded by the PYCARD gene. Epigenetic silencing of PYCARD (via DNA methylation at the promoter) has been observed to suppress inflammasome activity. Sulforaphane and other Nrf2 activators can influence epigenetic regulation. This is speculative but directionally interesting for a Role 2 (pharma-translation) collaborator's lab work.

CP4 — Caspase-1¶

Mechanism: ASC speck recruits and activates caspase-1 via CARD-CARD interactions. Active caspase-1 cleaves pro-IL-1β → IL-1β, pro-IL-18 → IL-18, and gasdermin D → GSDMD-N (pore-forming fragment). Caspase-1 is the single executioner of the inflammasome output.

VX-765 (Belnacasan)¶

Mechanism: Prodrug → metabolized to VRT-043198 → potent, selective, reversible caspase-1 inhibitor. Blocks cleavage of pro-IL-1β, pro-IL-18, and gasdermin D simultaneously.

VX-765 is the most advanced caspase-1 inhibitor to reach clinical trials. It's a prodrug that converts to VRT-043198, which sits in the caspase-1 active site and blocks substrate cleavage. It was well-tolerated in human Phase 2a trials (epilepsy) but didn't show sufficient efficacy for that indication. For gout, the mechanism is directly relevant — caspase-1 is THE enzyme that activates IL-1β from MSU crystal-driven inflammasome assembly.

Status: clinical development appears paused. VX-765 is available from research chemical suppliers (Selleck Chem, MedChemExpress, APExBIO) as a research compound. Z-YVAD-FMK is another research-grade caspase-1 inhibitor available from the same sources.

Direct natural caspase-1 inhibitors are rare because caspase-1 activation depends on the physical ASC platform — it's a structural activation, not a simple enzyme-substrate interaction. But several compounds indirectly reduce caspase-1 activation:

Procyanidin B2 (grape seed): Reduces MSU crystal-induced caspase-1 cleavage and IL-1β secretion in macrophages. Targets cathepsin B (released from ruptured lysosomes) which is required for caspase-1 activation. 200–400 mg grape seed extract/day.

Epigallocatechin gallate (EGCG): Suppresses caspase-1 activity in macrophages. Also blocks NF-κB (CP1) and IL-1β downstream (CP5). 400–800 mg/day or 3–5 cups matcha.

Berberine (again): Dose-dependently reduces caspase-1 mRNA expression and protein levels. This is berberine's CP4 contribution on top of its CP1 effects.

Theoretically, yes. A. oryzae can be engineered to produce recombinant proteins. If you cloned a caspase-1 inhibitory peptide or a VRT-043198-like small molecule biosynthesis pathway into the koji, it could produce it during fermentation. The challenge: caspase-1 inhibitors are typically not small peptides but rather peptidomimetic compounds. A more realistic koji angle: engineer it to overproduce compounds like procyanidin precursors or EGCG-like polyphenols that indirectly suppress caspase-1.

CP5 — IL-1β / IL-18 Output¶

Mechanism: The payload step. Mature IL-1β binds IL-1R1 on target cells → MyD88/IRAK → NF-κB → second wave of inflammation + neutrophil recruitment. CP5 splits into CP5a — receptor blockade (pharma biologics, the "off switch") and CP5b — active resolution via ALX/FPR2 (SPMs — the "resolve on command" switch, distinct from suppression).

CP5a — Receptor Blockade (Anakinra, Canakinumab, Rilonacept)¶

Anakinra (Kineret) and Canakinumab (Ilaris)¶

Mechanism: Recombinant IL-1 receptor antagonist (IL-1Ra) → competitive antagonist at IL-1R1 → blocks IL-1β AND IL-1α from binding receptor → shuts down all IL-1 signaling

Anakinra is the nuclear option at this chokepoint. It's a recombinant version of the body's own IL-1 receptor antagonist. In gout, it's used for patients who can't tolerate colchicine or NSAIDs. Single injection can abort a flare within hours. FDA-approved (for RA and CAPS), used off-label for gout.

Limitation: 100 mg daily subcutaneous injection, short half-life (~4-6 hours). Expensive without insurance. But it proves the concept: blocking IL-1 signaling is sufficient to stop a gout flare.

Anakinra SC for acute gout flare — off-label protocol (added 2026-05-17, source: gout-action-guide.md): 100 mg SC daily × 3 days, self-administered in thigh/abdomen (same SC route as insulin). NOT intra-articular — no needle into the gout joint itself. Mechanism: recombinant IL-1Ra competitively blocks IL-1β signaling — aborts flare within hours via the same CP5a chokepoint as canakinumab, but daily SC dosing vs. canakinumab's monthly SC + ~100× lower cost. Vs. prednisone 30-40 mg/day × 2-week taper: anakinra is faster onset (hours vs. days), narrower mechanism (single pathway block vs. system-wide glucocorticoid receptor), cleaner cumulative side-effect burden over years of recurrent flares (no bone loss, no glucose intolerance, no adrenal suppression, no mood/sleep/BP effects). Cost: ~$300/dose, ~$900/flare for the 3-day protocol. Access: rheumatologist or forward-thinking internist willing to prescribe off-label. Evidence level: Clinical Trial for approved indications; off-label gout use supported by the 2018 Sobi non-inferiority trial (NCT03002974) vs. triamcinolone. (source: gout-action-guide.md, gout-clinical-pipeline.md)

Canakinumab (Ilaris) status update: As of August 2023, canakinumab (anti-IL-1β mAb) became the first biologic formally FDA-approved for gout in the US, 12 years after its initial 2011 rejection. Long half-life (8 weeks), one SC injection covers months. Cost remains the limitation (~$300K/year). (Clinical Trial; J Inflamm Res 2026;19, PMID: 41867470. source: gout-clinical-pipeline.md)

Topical CBD+THC for acute flare — adjunct protocol (added 2026-05-17, source: gout-action-guide.md): 1:1 CBD:THC (high-mg/oz formulation) applied to the affected joint, plus ice cycling (10–15 min ice → apply topical → ice again 30–60 min later). CB2 receptor activation on synovial macrophages and infiltrating neutrophils suppresses NLRP3 inflammasome assembly and reduces IL-1β release — same downstream chokepoint CP2/CP3 as colchicine, reached via a different receptor. Topical TRPV1 desensitization plus cooling adds thermoreceptor-mediated pain reduction at the site. For recurrent-flare patients with significant cumulative steroid burden, this protocol may reduce or replace the need for prednisone dose escalation during a step-down rebound. Cannabis is jurisdiction-dependent and requires medical-program access in many places. Evidence level: In Vitro / Animal Model for the mechanism (see cannabinoids-terpenes.md §1 + §2 for per-compound evidence); direct human gout-flare RCT evidence absent. (source: gout-action-guide.md, cannabinoids-terpenes.md)

Your body makes its own IL-1 receptor antagonist (IL-1Ra). You can upregulate it:

Omega-3 SPMs (again — this is their home chokepoint): EPA → Resolvin E1 (RvE1), DHA → Resolvin D1/D2 (RvD1/D2), Protectin D1 (PD1), Maresin 1 (MaR1). These aren't just "anti-inflammatory" — they're pro-resolving. They command neutrophils to stop infiltrating, tell macrophages to switch from M1→M2, promote efferocytosis (cleanup of dead neutrophils), and reduce IL-1β signaling at target cells. This is active resolution, not just suppression.

Exercise: Acute exercise transiently increases IL-1Ra. The anti-inflammatory cytokine IL-6 released during exercise subsequently triggers IL-1Ra and IL-10 production. Regular moderate exercise maintains elevated baseline IL-1Ra. Don't exercise during a flare, but consistent training between flares raises your anti-inflammatory baseline.

EGCG (green tea): Suppresses IL-1β secretion from macrophages and reduces IL-1β-induced downstream signaling in target cells (chondrocytes, synoviocytes). Matcha provides the highest concentration.

Direct SPM supplements: SPM Active (Metagenics) provides pre-formed resolvins and protectins. Bypasses the conversion bottleneck. 2 softgels/day standardized to 17-HDHA and 18-HEPE (SPM precursors).

CP5b — Active Resolution via ALX/FPR2 (SPMs)¶

Mechanism: Specialized pro-resolving mediators (SPMs) — Resolvins (RvE1 from EPA; RvD1/D2 from DHA), Protectins (PD1), Maresins (MaR1) — bind ALX/FPR2, ChemR23/CMKLR1, GPR32, GPR18 receptors on leukocytes to actively command the resolution program: stop neutrophil infiltration, M1→M2 macrophage switch, promote efferocytosis. Distinct from suppression — this is "stand down" signaling.

Direct MSU gout animal evidence: - RvD1 in MSU mouse gouty arthritis (Zaninelli 2022 Br J Pharmacol PMID 35716378) — intrathecal + IP RvD1 reduced mechanical hyperalgesia, IL-1β, leukocyte recruitment, NF-κB phosphorylation, ASC specks, and CGRP; revealed a nociceptor-macrophage resolution axis. (Animal Model.) - MaR1 in MSU peritonitis (Jiang 2023 Mol Med PMID 37996809) — MaR1 acts via Prdx5 upregulation + AMPK/Nrf2. (Animal Model.) - Zaninelli Expert Opin Ther Targets 2023 (PMID 37651647) — explicitly names ALX/FPR2 agonism as a priority gout therapeutic target.

Complement-resolution link: Aggregated neutrophil extracellular traps (aggNETs) resolve gout by sequestering cytokines/chemokines (Schauer Nat Med 2014 PMID 24784231). aggNETs are the resolution form of NET release downstream of GSDMD pore-driven neutrophil death (CP6b). Tophi are chronic aggNETs — unresolved resolution. SPM signaling is required for NET resolution to complete; deficit = prolonged flare.

Therapeutic access points: - Direct SPMs: SPM Active (Metagenics) — pre-formed resolvin mix; 2 softgels/day. - Precursors: EPA/DHA omega-3 — 3–4 g/day; substrate conversion efficiency ~5–10%. - Aspirin-triggered resolvins: low-dose aspirin shifts COX-2 to aspirin-acetylated form that generates 15-epi-LXA4 and 17R-RvD series. - Lactoferrin — fermentable at 3.5 g/L in P. pastoris (PMID 37926296); indirect resolution via multiple pathways, partial overlap with SPM signaling. Round 1 CP5 addition.

Deep dive: spm-resolution-pathway.md

CP6 — Neutrophil Amplification + Pyroptotic Exit¶

Mechanism: Renamed from "Gasdermin D" to acknowledge that the exit-route chokepoint is dominated by two cooperating amplification loops in gout: (a) 5-LOX → LTB4 → neutrophil chemotaxis (CP6a) and (b) GSDMD pore formation → pyroptotic IL-1β release → aggNET amplification (CP6b). Blocking either chokes the flare amplification loop.

CP6a — 5-LOX → LTB4 → Neutrophil Chemotaxis¶

Mechanism: 5-lipoxygenase (5-LOX, encoded by ALOX5) converts arachidonic acid → LTA4 → LTB4, the most potent endogenous neutrophil chemoattractant. Gout flares are neutrophil-driven storms; cutting LTB4 production cuts the amplification loop. Substrate competition with EPA redirects 5-LOX toward the resolving RvE1 series instead of pro-inflammatory LTB4.

Exploits at CP6a: - Quercetin — 300 nM IC50 against 5-LOX (ChEMBL v34, J Med Chem 1991). Among the most potent curated direct bioactivities for quercetin at any target; 36× more potent than its NLRP3-pathway functional IC50. Gout-relevant via LTB4 blockade. - AKBA (acetyl-11-keto-β-boswellic acid from Boswellia) — allosteric 5-LOX inhibitor, ~2.7 μM cellular IC50 (Werz group, J Nat Prod 2000). Clinically used as Boswellin / 5-Loxin. - EPA substrate competition — loading EPA redirects 5-LOX away from arachidonic-acid-derived LTB4 and toward the resolving RvE1 series (connects CP6a to CP5b SPM resolution). - Salidroside (from Rhodiola rosea) — MSU-gout validation per PMID 30265377 (animal model); 5-LOX suppression is one of its reported mechanisms.

Zileuton (Zyflo / Zyflo CR, FDA-approved for asthma) — oral 5-LOX inhibitor, the only approved direct 5-LOX drug in the US. Never tested in gout despite mechanism match at CP6a. Dose precedent: 1,200 mg BID (controlled-release). Hepatotoxicity monitoring required (boxed warning). Zero gout trials registered on ClinicalTrials.gov as of 2026-05-05 — a complete pipeline gap, not a buried negative result. A latent repurposing candidate that has been overlooked because gout → NLRP3 (CP2) attracted all the pharma R&D attention; the 5-LOX / neutrophil-amplification branch (CP6a) is unrepresented in gout trial registries. See zileuton.md for the full dossier. (Clinical Trial for asthma; Mechanistic Extrapolation for gout; source: zileuton.md)

This is a first-class chokepoint, not a side annotation. Gout is neutrophil-dominated at the tissue level; LTB4 is the primary chemoattractant driving that infiltration; and food-derived 300 nM-IC50 inhibitors are available. Missing this branch in the pre-v1.2 map was the single biggest gap in the exploit coverage.

CP6b — Gasdermin D Pore Formation (Pyroptotic Exit)¶

Mechanism: GSDMD cleaved by caspase-1 → N-terminal fragment oligomerizes into plasma-membrane pores → IL-1β release + pyroptotic cell death. Downstream effect: GSDMD pore-driven neutrophil death → NET release → aggNET resolution form (Schauer Nat Med 2014 PMID 24784231). Blocking GSDMD pore formation prevents IL-1β amplification and preserves NET integrity for resolution (aggNET) rather than uncontrolled NETosis.

Disulfiram (Antabuse)¶

Mechanism: Covalently modifies Cys191 (human) / Cys192 (mouse) in GSDMD → blocks pore formation specifically. Does NOT block caspase-1 cleavage of GSDMD — it allows processing but prevents the processed fragment from forming pores.

This is the black hat's dream exploit. Disulfiram — Antabuse — the drug prescribed to alcoholics since the 1950s — was discovered in 2020 (Nature Immunology) to specifically block gasdermin D pore formation at nanomolar concentrations. It covalently modifies Cys191 on GSDMD, preventing the N-terminal fragment from oligomerizing into membrane pores.

The elegance: disulfiram still allows IL-1β and GSDMD processing (caspase-1 can still cleave them) but abrogates pore formation. No pores = IL-1β stays trapped inside the cell. No pores = no pyroptosis = no inflammatory amplification from cell death.

It's FDA-approved. It has 70+ years of safety data. It costs ~$30/month. You can get a prescription by... having a conversation with a doctor about alcohol use disorder, or by finding a physician interested in repurposed drug applications. This is the single most accessible pharma-grade NLRP3 pathway exploit in this entire document.

DMF (Tecfidera) is FDA-approved for multiple sclerosis. The 2020 Science paper revealed an entirely new mechanism of action: DMF succinates gasdermin D, forming S-(2-succinyl)-cysteine at Cys191. This blocks the caspase-1-GSDMD interaction entirely, preventing cleavage, oligomerization, pore formation, and pyroptosis.

Clinical evidence: MS patients taking DMF had reduced levels of both IL-1β and GSDMD-N (the cleaved pore-forming fragment) in their blood. The drug is already suppressing pyroptosis in humans at prescribed doses.

Access: prescription for MS. Off-label use would require a sympathetic neurologist or a creative conversation. More expensive than disulfiram. But it hits GSDMD through a different mechanism — and also activates Nrf2 (hitting CP1 simultaneously).

NSA modifies the same Cys191 residue on GSDMD as disulfiram. Research compound only — not clinically available. But it confirms that Cys191 is the universal vulnerability on gasdermin D. Any compound that hits this cysteine blocks the exit route.

Lactoferrin — fermentable CP6b option (Shan 2026 PMID 41524100). Shan et al. 2026 (Food Funct 17:1045-60) demonstrated that lactoferrin pretreatment inhibited NLRP3/caspase-1/GSDMD pyroptosis in a radiation-induced intestinal injury model (10 Gy C57BL/6 mice + 4 Gy IEC-6 cells) and activated PINK1/Parkin + FUNDC1/BNIP3/NIX mitophagy. Pharmacological mitophagy inhibition (3-MA, Mdivi-1) abolished the protection — the mitophagy-induction arm is mechanistically required. This makes lactoferrin the only fermentable food-grade CP6b option in the Open Enzyme platform; disulfiram and DMF are pharma-only. Lactoferrin's CP6b mechanism is upstream of GSDMD pore formation (mitophagy clears damaged mitochondria before they trigger GSDMD cleavage), distinct from disulfiram's direct Cys191 modification. Evidence level: Animal Model + In Vitro (Supported). See lactoferrin.md §4.1 and koji-endgame-strain.md §2.2 for the full coverage matrix. (source: koji-endgame-strain.md, lactoferrin.md)

Compound	Dose	Chokepoints Hit	Timing
KPV Nasal Spray	200–500 mcg/day	`CP1`	Morning (combine with BPC-157 spray)
BPC-157 Nasal Spray	200–500 mcg/day	`CP1`	Morning (already taking)
TB-500	2–5 mg 2x/week	`CP1` `CP2`	Injection days or nasal spray daily
Omega-3 (high EPA)	3–4g EPA+DHA/day	`CP1` `CP5`	With meals (split AM/PM)
Sulforaphane / Broccoli Sprouts	~50 mg SFN or 100g sprouts	`CP1` `CP2`	Morning with food
Curcumin (NovaSOL or Theracurmin)	500–1000 mg/day	`CP1`	With meals
Berberine	500 mg 2x/day	`CP1` `CP4`	With meals (also helps Lynn's SIBO)
Oridonin (Rabdosia extract)	50–100 mg/day	`CP1` `CP2`	With meals
NAC	1200 mg/day	`CP2`	Morning, empty stomach
MitoQ	10–20 mg/day	`CP2`	Morning, empty stomach
Quercetin (Phytosome)	500–1000 mg/day	`CP1`	With meals (also blocks xanthine oxidase)
Spermidine	1–3 mg/day	`CP2` `CP3`	Morning
Trehalose	5–10g/day	`CP2`	In coffee/tea (sugar substitute)
Grape Seed Extract	300 mg/day	`CP2` `CP4`	With meals
Vitamin D3 + K2	5000–10000 IU D3 + 200 mcg K2	`CP1`	With fatty meal

1. Multi-Chokepoint Compounds (The MVPs)¶

Mechanism: Compounds that hit 3+ chokepoints deserve disproportionate weight in the stack

BHB (ketones): Blocks priming (CP1), prevents K⁺ efflux (CP2), reduces ASC oligomerization (CP3). Three chokepoints from one metabolite that your liver makes for free when you fast. This is the single most efficient exploit in the entire map.

Berberine: Suppresses NF-κB/TLR4 (CP1), reduces NLRP3/ASC/caspase-1 mRNA (CP1+CP4), remodels gut microbiota to reduce LPS priming (CP1). Plus: SIBO treatment for Lynn, blood sugar regulation, antimicrobial. It's the Swiss Army knife.

Oridonin: Covalent NLRP3 inhibitor (CP2), NF-κB suppressor (CP1), Nrf2 activator (CP1+CP2). A natural compound that mimics a pharma-grade NLRP3 inhibitor.

Dimethyl Fumarate: Nrf2 activator (CP1+CP2) AND gasdermin D succinator (CP6). Bridges the first and last chokepoints.

EGCG: NF-κB inhibitor (CP1), caspase-1 suppressor (CP4), IL-1β blocker (CP5). Three downstream chokepoints from drinking tea.

Cross-Reference: Peptide Mechanisms

Several compounds in this exploit map overlap with the Peptides & Gout Addendum. Specifically: BPC-157 (CP1 — NF-κB/NO modulation, macrophage cytoprotection), KPV (CP1 — NF-κB suppression via α-MSH pathway, CP2 — downstream inflammasome dampening), and TB-500 (CP1 — NF-κB suppression, tissue repair acceleration). The peptide doc covers dosing, ROA, and sourcing details. The key insight from mapping them here: KPV hits Chokepoints 1 and 2, but BHB hits Chokepoints 1, 2, and 3 — making ketosis/fasting potentially more impactful than any individual peptide for inflammasome suppression.

2. Things You're Already Doing That Help¶

Mechanism: Hidden value in current protocols

BPC-157 nasal spray: Beyond tissue healing, BPC-157 modulates the NO system and has cytoprotective effects on macrophages. It may be reducing the severity of MSU crystal-induced macrophage activation — protecting the cells that would otherwise be damaged and release inflammatory signals.

Exploring fermented foods: Fermentation naturally produces spermidine, trehalose, and various polyphenols. Traditional fermented foods (miso, natto, kimchi) contain significant spermidine — you're getting CP2/CP3 autophagy benefits from the fermentation interest itself. Natto specifically contains nattokinase (fibrinolytic) and is one of the richest food sources of spermidine (~70 nmol/g).

The koji project itself: Even without the uricase gene, traditional koji fermentation produces proteases that break down proteins into bioactive peptides, some of which have anti-inflammatory properties. The fermentation platform is inherently producing helpful compounds.

3. The Koji Superorganism Opportunity¶

Mechanism: Engineering A. oryzae as a multi-target therapeutic food platform

The engineered koji vision shouldn't stop at uricase. A. oryzae has GRAS status, a well-characterized genome, and modern CRISPR tools. The synthetic biology toolkit includes tunable promoters, neutral integration loci, and bidirectional promoters. You could engineer a single organism that produces:

Uricase — dissolves uric acid (upstream of everything)
KPV-like anti-inflammatory peptides — NF-κB suppression (CP1)
Enhanced spermidine biosynthesis — autophagy activation (CP2/CP3)
Nrf2-activating compounds — antioxidant defense (CP1/CP2)

This is the vision: a single fermented food that attacks gout from both the uric acid side and the inflammatory side simultaneously. Pharma-translation lab work on the uricase gene is the first module. Each additional module makes the platform more powerful. And because it's a food organism producing these compounds during fermentation, it doesn't require pharma-grade purification or regulatory approval as a drug — it's a fermented food product.

4. The SIBO–Gout–Lynn Connection¶

Mechanism: NLRP3 inflammasome is central to both conditions

NLRP3 inflammasome activation is a core driver of intestinal inflammation in SIBO and IBD. The same compounds that suppress your gout cascade suppress Lynn's gut inflammation:

Berberine: SIBO eradication (comparable to rifaximin) + NLRP3 suppression + NF-κB inhibition + gut microbiota remodeling. This is literally the same drug for both conditions through the same mechanism.

KPV peptide: Originally studied for IBD/colitis (PepT1-mediated intestinal uptake). KPV reduces intestinal inflammation via NF-κB suppression in gut epithelium AND systemic inflammation driving gout. Oral/sublingual KPV reaches the gut directly.

Omega-3 SPMs: Resolve intestinal inflammation AND joint inflammation. Same mediators, different tissues.

BHB/fasting: Suppresses NLRP3 in gut macrophages AND joint macrophages. The inflammasome doesn't care which tissue it's in — BHB blocks it everywhere.

Spermidine + Trehalose: Autophagy enhancement protects gut barrier integrity AND prevents macrophage NLRP3 activation in joints.

Bottom line: build ONE stack, share it. Most of these compounds are household-level interventions that benefit both conditions through the shared NLRP3 mechanism.

SIBO is now the leading candidate diagnosis for Lynn's digestive issues (see Enzyme Deficit Deep Dive). This makes the shared NLRP3 pathway even more clinically relevant — it's not a theoretical overlap, it's the same inflammatory mechanism driving symptoms in both Brian and Lynn. Wild-type koji already addresses Lynn's enzyme needs without engineering (the supplement industry's fungal enzymes are industrial koji fermentation). The full platform vision is mapped in the Open Enzyme Vision.

5. The Surprising & Counterintuitive¶

Mechanism: Things that weren't obvious going in

Ketosis paradox resolved during intercritical periods: The conventional wisdom that ketosis is bad for gout (because ketones compete with uric acid for renal excretion) misses the bigger picture for prophylaxis. Yes, BHB transiently raises serum uric acid — but it simultaneously and potently suppresses the NLRP3 inflammasome that turns those crystals into pain. With koji-uricase handling uric acid levels, ketosis becomes net-beneficial as a prophylactic NLRP3 tool. The temporal boundary matters: during an active flare or prodrome, the ketotic UA spike compounds the inflammatory substrate; ketosis should be suspended until the flare resolves. The uricase project doesn't just enable gout control — it unlocks ketosis as a prophylactic therapeutic strategy by reducing the inter-flare downside; the acute-flare contraindication remains. See bhb-ketones.md §"Contraindications" and gout-action-guide.md §"Active flare".

Disulfiram is the most underrated gout drug on Earth: An FDA-approved drug with 70 years of safety data, costing $30/month, that blocks the final step of IL-1β release and prevents pyroptotic amplification — and nobody in rheumatology is talking about it because it was discovered by immunologists studying sepsis. This is a market inefficiency in medical knowledge.

Colchicine is better than we thought: We used to think colchicine worked by being a general anti-inflammatory. Now we know it specifically disrupts microtubule-mediated ASC speck formation. This means it doesn't just reduce inflammation — it prevents the inflammasome platform from assembling. It's a targeted NLRP3 pathway disruptor, not a blunt instrument.

Autophagy is the cleanup crew nobody hired: Spermidine, trehalose, fasting, and rapamycin all enhance autophagy, which clears the damaged mitochondria that trigger NLRP3. This is the body's built-in defense against inflammasome activation. Most people's autophagy is suppressed by constant eating, sedentary behavior, and mTOR over-activation. Simply restoring normal autophagy (fasting + spermidine) may be one of the most impactful interventions.

The crystal dissolution danger window: When uric acid-lowering therapy (including koji-uricase) starts dissolving existing MSU crystal deposits, the crystals temporarily become smaller with more surface area, and crystal shedding from tophi can trigger acute flares. This is why the NLRP3 stack isn't just a bridge — it's essential during the crystal dissolution phase. You need both strategies running simultaneously. The koji dissolves the crystals while the stack prevents the dissolution from triggering flares.

Quercetin's triple life: Quercetin is (1) an NF-κB inhibitor (CP1a of the NLRP3 pathway), (2) a xanthine oxidase inhibitor (like allopurinol — blocks uric acid production), and (3) a 300 nM IC50 5-LOX inhibitor (ChEMBL v34, J Med Chem 1991) that blocks LTB4-mediated neutrophil chemotaxis — now a named branch of the map as CP6a (see "Neutrophil Amplification + Pyroptotic Exit"). Quercetin attacks gout from the inflammatory side (CP1a), the metabolic side (xanthine oxidase), and the neutrophil-recruitment side (CP6a 5-LOX/LTB4) in one molecule. Phytosome form (Quercefit) solves the bioavailability problem. The 5-LOX leg was identified in the 2026-04-23 ChEMBL cross-check and is represented as CP6a in the v1.2 map. (In Vitro; source: nlrp3-inhibitor-screen.md)

Chokepoint Coverage Completeness Audit (added 2026-05-19)¶

A pass over the corpus across CP0 → CP6b reveals an emergent platform pattern: every NLRP3 chokepoint now has at least one named intervention in the Open Enzyme corpus. Coverage isn't uniformly fermentable — some chokepoints have only pharma-class interventions today — but the named-intervention coverage is complete. The table below maps each chokepoint × intervention pair, tagged by status tier so the actual coverage landscape (vs. the implicit one) is legible at a glance.

Status tiers (per Pass 3 2026-05-17 correction — distinguishes categories that the daemon's "pharma-only" framing collapsed):

Clinical (today) — FDA-approved drug in standard or off-label clinical use
Pharma-only (no gout indication) — pharma exists for other indications; not in standard gout practice
OE engineering-pending — in Open Enzyme development pipeline; chassis or wet-lab gate ahead
OE fermentable (today) — accessible via cultivation / fermentation / dietary intake at consumer scale

Chokepoint	Intervention	Status	Reference
CP0 — Crystal-triggered C5a priming	Avacopan (C5aR1 antagonist)	Clinical (gout off-label)	`complement-c5a-gout.md`
CP0	DAF/CD55 SCR1-4 (engineered secreted complement regulator)	OE engineering-pending (§1.25 wet-lab gate)	`daf-cd55-scr14-truncated-computational.md`
CP0	C1-INH (serpin) on engineered LBP chassis	OE engineering-pending (comp-037)	`c1-inh-protease-stability-ecn-computational.md`
CP0	Rosmarinic acid (dietary C3 convertase inhibitor)	OE fermentable	`upstream-complement-modulator-sweep-computational.md`
CP0	Houttuynia cordata polysaccharide	OE fermentable	comp-018 / comp-020
CP1a — NF-κB priming (transcriptional)	EGCG (proteasome / NF-κB)	OE fermentable	`egcg.md`
CP1a	KPV peptide	OE engineering-pending (koji cassette)	`kpv-peptide.md`
CP1a	Lactoferrin	OE engineering-pending (koji + chaperone framework)	`lactoferrin.md`
CP1a	Theaflavins (TF3 via TNFSF14/HVEM modulation)	OE fermentable (black tea)	`theaflavins.md`
CP1b — C5a → ROS priming (non-transcriptional)	Ergothioneine (mitochondria-targeted thiol antioxidant)	OE fermentable (Pleurotus + koji)	`medicinal-mushroom-complement-track.md`
CP1b	NAC, MitoQ	Clinical (OTC)	—
CP1+CP2	Glucocorticoid receptor (GR) signaling — endogenous cortisol + prednisone	Clinical (pharma, gout standard)	§"Glucocorticoid Receptor Signaling" above
CP2 — K⁺ efflux / NLRP3 conformational activation	Colchicine (β-tubulin + P2X7)	Clinical (pharma, gout gold-standard acute flare)	`colchicine.md`
CP2	BHB (fasting/ketosis; potassium efflux block, ASC reduction)	OE fermentable (endogenous + supplement)	`bhb-ketones.md`
CP2	Topical CBD:THC (CB2 → NLRP3)	OE fermentable (cannabis, jurisdiction-dependent)	`cannabinoids-terpenes.md`
CP2	Theaflavins (NEK7-NLRP3 disruption)	OE fermentable (black tea)	`theaflavins.md`
CP2	Oridonin (NLRP3 Cys279 covalent)	OE fermentable (Rabdosia rubescens)	`oridonin.md`
CP3 — ASC speck assembly	Colchicine (microtubule-mediated ASC transport block)	Clinical (pharma, same mechanism as CP2)	`colchicine.md`
CP3	Theaflavins (ASC speck inhibition)	OE fermentable	`theaflavins.md`
CP3	Spermidine	OE fermentable (dietary polyamine)	`nlrp3-exploit-map.md` §CP3
CP4 — Caspase-1 activation	VX-765 (belnacasan)	Pharma-only (no gout indication; previously trialed for epilepsy)	—
CP4	Berkeleyamides (Talaromyces amestolkiae, CASP1 IC50 330/610 nM)	OE engineering-pending (BGC heterologous to koji per J1 walkthrough)	`medicinal-mushroom-complement-track.md` §"Ascomycete secondary metabolites"
CP5a — IL-1β receptor blockade	Anakinra (IL-1RA, SC)	Clinical (pharma, gout off-label per `gout-action-guide.md`)	`gout-action-guide.md` §"Active flare"
CP5a	Canakinumab (anti-IL-1β mAb)	Clinical (pharma, FDA gout)	`gout-clinical-pipeline.md`
CP5a	Rilonacept (IL-1 trap)	Clinical (pharma)	`gout-clinical-pipeline.md`
CP5a	Inhaled mRNA-IL-1RA (comp-036)	OE engineering-pending (chassis-pending)	`chassis-pending-interventions.md`
CP5b — SPM resolution (ALX/FPR2)	Omega-3 DHA/EPA (precursors to resolvins/protectins)	OE fermentable (dietary)	`spm-resolution-pathway.md`
CP6a — 5-LOX / LTB4 neutrophil amplification	Zileuton	Pharma-only (FDA asthma)	`zileuton.md`
CP6a	Quercetin (5-LOX catalytic IC50 ~300 nM)	OE fermentable (Quercefit phytosome)	`nlrp3-exploit-map.md` §CP6
CP6a	AKBA / Boswellia (5-LOX allosteric + mPGES-1)	OE fermentable	`nlrp3-exploit-map.md` §CP6
CP6b — GSDMD pyroptotic exit	Disulfiram (repurposed)	Pharma repurposable (FDA alcohol use disorder)	`disulfiram.md`

Two gaps the audit makes visible:

CP4 — caspase-1: VX-765 (pharma-only, no gout indication) + Berkeleyamides (OE engineering-pending). No OE-fermentable today. The Berkeleyamide → koji-heterologous-BGC path is the platform's only fermentable-coverage hope at CP4; until that lands, CP4 is the chokepoint with the thinnest OE coverage.
CP5a — IL-1β receptor: clinical-pharma coverage is robust (anakinra, canakinumab, rilonacept) and inhaled mRNA-IL-1RA is queued, but no OE-fermentable intervention exists for direct IL-1 receptor blockade. This is a fundamental architecture constraint: IL-1β receptor blockade requires either a protein antagonist (IL-1Ra family) or a high-affinity antibody — neither is plausibly fermentation-accessible at consumer scale without engineered LBP-class delivery (which is the inhaled-mRNA path).

What the audit confirms: every other chokepoint (CP0, CP1a, CP1b, CP2, CP3, CP5b, CP6a, CP6b) has at least one OE-fermentable intervention available today. The platform's named-coverage is broad. Coverage gaps are tractable (CP4) or architecturally constrained (CP5a) rather than mysterious.

Use this table for: (a) gap analysis when scoping new comp-NNN computational experiments — empty cells in the OE-fermentable column for a given chokepoint are platform-relevant research opportunities; (b) onboarding readers who need a single-glance view of platform coverage before diving into per-chokepoint detail.

AI Analysis Updates — April 2026: Microbial Production Candidates¶

Systematic evaluation of NLRP3 inhibitors producible by engineered microbes reveals a surprising landscape: while synthetic NLRP3 inhibitors (MCC950, dapansutrile) are 100–10,000× more potent than food-derived candidates, several compounds combine measurable NLRP3 activity with commercial-scale fermentation capacity. This section synthesizes findings from ai-analysis/07-nlrp3-inhibitor-screen.md and identifies production feasibility, evidence strength, and strategic positioning.

Ursolic Acid: Primary Production Candidate¶

Mechanism: Blocks NF-κB, AP-1, and NLRP3 assembly. Multi-target inhibitor with established gout-relevant validation pathway.

Production: 8.59 g/L in S. cerevisiae bioreactor (2024 industry record). GRAS status (apples, rosemary). Scalable to gram-scale.

Evidence: - NF-κB and AP-1 inhibition (in vitro, multiple studies) - NLRP3 assembly blockade (in vitro, macrophage activation assays) - Kawasaki disease vascular injury reduction (animal model, murine, showing inflammasome-related pathology suppression) - Gap: No direct gout testing published. Mechanistic extrapolation: ursolic acid's multi-target inflammasome suppression in vascular injury models suggests efficacy in MSU-driven NLRP3 cascade.

Strategic position: Highest TRL (Technology Readiness Level 8–9). Immediate fermentation feasibility via S. cerevisiae engineering. Could be first production candidate for koji co-fermentation.

Cross-reference: [[NLRP3 inflammasome activation]] — ursolic acid hits Chokepoints 1 and 2 simultaneously.

Quercetin: Dual-Target Exploitation Validated in Gout¶

Mechanism: NF-κB inhibition (CP1) + xanthine oxidase inhibition (uric acid production blockade). Double life in inflammatory and metabolic domains.

Production: 930 mg/L in S. cerevisiae (confirmed). TRL 6. Phytosome form (Quercefit) achieves 20× bioavailability improvement.

Evidence: - 70–80% IL-1β reduction in THP-1 macrophages (in vitro) - Gout-specific validation: MSU-induced arthritis reduction in rats (animal model). Direct inflammatory flare suppression. - Xanthine oxidase inhibition (in vitro kinetic assays, comparable to allopurinol binding mode) - GRAS dietary source (onions, apples)

Strategic position: Gout-validated, multi-mechanism exploitation. Existing doc reference (line 110) correctly identifies the double life; this analysis confirms production scalability. Integration into engineered koji would provide both inflammasome suppression AND uric acid production reduction — a rare dual-pathway exploit.

Cross-reference: [[uricase]] and [[gout-deep-dive]] — quercetin complements enzymatic uric acid degradation with metabolic suppression.

Carnosine: Unique Hyperuricemia + NLRP3 Signature¶

Mechanism: ROS scavenging, p-p65 suppression, p-JNK dampening, NLRP3 direct inhibition, URAT1 and GLUT9 transporter modulation.

Production: ~150 mg/L estimated. Lower than ursolic acid or quercetin, but mechanistic uniqueness is disproportionately valuable.

Evidence: - Published hyperuricemia rat data (animal model): Carnosine reduces serum uric acid levels AND suppresses NLRP3 inflammasome activation simultaneously. This is the ONLY candidate with this dual phenotype documented in gout-relevant preclinical models. - Multi-target mechanistic profile: blocks multiple pathway layers (ROS → NF-κB → NLRP3; also addresses renal urate handling via URAT1/GLUT9). - GRAS precursor status (amino acid derivative, endogenous in muscle)

Strategic position: Candidate-of-choice if hyperuricemia and inflammasome control must be addressed by a single compound. The hyperuricemia data in rats bridges the enzyme deficit and inflammatory axes simultaneously. Carnosine is mechanistically what you're trying to build with koji + stack — compressing two problems into one molecule.

Critical note: Estimated production yield is lower than front-runners. Feasibility study needed before committing to carnosine-focused engineering.

Cross-reference: [[enzyme-deficit-deep-dive]] and [[NLRP3 inflammasome activation]] — carnosine addresses both peripheral conditions of the gout problem.

Taurine: Native Yeast Production, Potassium Efflux Block¶

Mechanism: Upstream blockade of K⁺ efflux (prevents inflammasome assembly trigger). Validated in sepsis and cardiac inflammation models.

Production: Native S. cerevisiae production. Endogenous pathway. Negligible engineering overhead. Gram-scale feasible.

Evidence: - K⁺ efflux prevention (in vitro patch clamp / inflammation assays) - Sepsis model validation (animal model, murine LPS challenge, shows NLRP3 suppression downstream of cytokine reduction) - Cardiac injury model validation (animal model, myocardial infarction, inflammasome-mediated damage reduction) - Gap: No gout-specific testing published. Mechanistic extrapolation: K⁺ efflux is a canonical NLRP3 activation trigger; blocking it upstream should suppress MSU-induced inflammasome activation.

Strategic position: Lowest engineering effort (native production). Strongest existing evidence in sepsis/cardiac contexts. Taurine co-fermentation in koji adds minimal burden while providing CP2 (NLRP3 activation) coverage through a distinct mechanism from ursolic acid or quercetin.

Cross-reference: [[nlrp3-inflammasome]] assembly mechanism — K⁺ efflux is the physical trigger; taurine blocks the trigger upstream of sensor activation.

Kojic Acid: A. oryzae Native, Potency Unknown — Immediate Screening Imperative¶

Mechanism: Established NF-κB suppression. NLRP3 activity NOT YET TESTED in published literature.

Production: A. oryzae naturally produces 3–5 g/L. Established fermentation. GRAS historical use (food colorant, cosmetics). No additional engineering required for baseline production.

Evidence: - NF-κB suppression in multiple cell types (in vitro, various inflammatory assays) - Critical gap: NLRP3 inflammasome activity is unpublished. Does kojic acid inhibit NLRP3 assembly, ASC speck formation, caspase-1 activation, or IL-1β secretion in MSU-challenged macrophages? Unknown.

Strategic recommendation: PRIORITY IMMEDIATE SCREENING. Run a THP-1 macrophage assay with MSU crystals ± kojic acid. Measure: NLRP3 oligomerization (Western blot / immunoprecipitation), ASC speck formation (fluorescence microscopy), caspase-1 cleavage (p20 subunit detection), IL-1β secretion (ELISA). If NLRP3-positive, kojic acid becomes candidate #1 by production metrics alone (3–5 g/L native production far exceeds all alternatives except ursolic acid). If NLRP3-inactive, deprioritize.

Strategic position: The highest upside / lowest effort if NLRP3 activity is confirmed. A. oryzae is already your koji platform; if natural kojic acid production inhibits NLRP3, you gain a multi-gram/liter compound for free during standard fermentation.

Cross-reference: [[engineered-koji-protocol]] — kojic acid screening is a natural module of koji fermentation optimization.

Taurine and Kojic Acid: Strategic Insight on Potency Gaps¶

All six candidates face a quantitative challenge: the benchmark pharma compounds (MCC950 at IC50 ~7.5 nM) are 100–10,000× more potent than food-derived candidates (ursolic acid, quercetin, carnosine, taurine all in the low-to-mid µM range for NLRP3 inhibition). This gap means:

Single-compound therapy is insufficient. No fermentation-derived candidate alone will replicate MCC950-level suppression at physiologically achievable doses.
Synergistic multi-target stacking is mandatory. Ursolic acid (NF-κB + AP-1 + NLRP3) + quercetin (NF-κB + xanthine oxidase) + carnosine (ROS + URAT1/GLUT9) + taurine (K⁺ efflux block) + kojic acid (NF-κB, if NLRP3-positive) attack gout through independent mechanisms. Their combined effect exceeds any single compound — not through additive potency, but through redundancy: if one mechanism fails, others suppress the cascade.
Clinical strategy implication: The engineered koji is not a replacement for MCC950-level drugs. It is a systemic, multi-target, fermentation-derived alternative that trades single-agent potency for pathway coverage. Combined with uricase (upstream crystal elimination) and the existing oral stack (BHB, berberine, EGCG, etc.), it provides continuous, food-level NLRP3 suppression. This may be sufficient for chronic gout management without pharma-grade inhibitors.

Cross-reference: [[nlrp3-exploit-map]] "Multi-Chokepoint Compounds" section — the existing doc articulates the strategy; this analysis identifies the fermentation candidates that execute it.

NLRP3 Exploit Map v1.2¶

Compiled April 2026 | For research and educational purposes

This document is a research synthesis, not medical advice. Discuss any changes with your physician.

"Every system has vulnerabilities. The question is whether you're the one finding them."

Open Enzyme Research Library¶

This document is part of the Open Enzyme project — an open-source therapeutic enzyme platform.

Research Documents¶

Open Enzyme Vision & Roadmap
Gout Deep Dive Research
Enzyme Deficit Deep Dive
NLRP3 Inflammasome Exploit Map (this document)
Peptides & Gout Addendum
Blood-Barrier Exploits
Engineered Koji Protocol
Engineered Yeast Uricase Proposal

Revision History¶

2026-05-05 (v1.4 additions): Updated CP0 platform gap status from "permanent honest gap" to "active engineering candidate with three wet-lab unknowns" — comp-012 confirmed DAF/CD55 SCR1-4 truncated construct (aa 35–285) is LOW protease risk (max 0.039, identical to uricase) under shio-koji conditions; hypothesis card H05 committed. Added chaperone-orthogonal stacking framework reference for multi-cassette koji yield prediction. Added comp-011 (C. utilis uricase cassette compatibility, MODERATE verdict) as follow-on to comp-010. (source: daf-cd55-scr14-truncated-computational.md, chaperone-orthogonal-stacking.md, c-utilis-uricase-cassette-compatibility-computational.md)

2026-05-05 (v1.3 additions): Added theaflavins (TF1/TF2A/TF2B/TF3) as a Tier 2 CP2/CP3 compound with direct MSU peritonitis Animal Model (Chen 2023 PMID 37221235) and unique URAT1/GLUT9 renal urate handling profile; added to CP1a (TF3 TNFSF14/HVEM modulation). Upgraded sulforaphane to Tier 2 with two additional direct MSU gout citations (Yang 2018 PMID 29340626 oral MSU foot-pad; Greaney 2015 PMID 26269198 Nrf2-independent inflammasome inhibition). Expanded zileuton CP6a entry with confirmed zero-gout-trials status (ClinicalTrials.gov 2026-05-05 search) and link to zileuton.md dossier. Updated uricase variant selection: C. utilis elevated to co-primary for oral/gut-lumen track based on industry-revealed preference (3-of-4 recent programs) and Tang 2025 directed evolution head-to-head (PMID 39892538). (source: theaflavins.md, nlrp3-inhibitor-screen.md, zileuton.md, uricase-variant-selection.md)

2026-04-24 (v1.2): Restructured from 6 chokepoints to 7 chokepoints with labeled sub-branches, following the "Beyond the 6-Chokepoint NLRP3 Map" exploit-vector audit. Changes: (1) Added CP0 — Crystal-Triggered Priming Signals (C5a-dominant) recognizing MSU→complement→C5a as the dominant priming signal in gout (Cumpelik 2016 PMID 26245757; Khameneh 2017 PMID 28167912), upstream of NF-κB; acknowledges honest platform gap — stack has zero fermentable C5a coverage; avacopan (FDA-approved C5aR1 antagonist) flagged as pharma adjunct. (2) Split CP1 into CP1a (NF-κB transcriptional priming, including TNFSF14/LIGHT amplifier) and CP1b (non-transcriptional C5a→ROS priming); annotated S100A8/A9-high CD14 monocytes as 2025 single-cell-defined flare driver (Alaswad et al. 2025 PMID 40023733). (3) Annotated CP2 as P2X7/P2X2-mediated K⁺ efflux, with colchicine as dual-hit CP2+CP3 (Leung 2015 PMID 26228647). (4) Split CP5 into CP5a (receptor blockade — anakinra, canakinumab, rilonacept) and CP5b (active resolution via ALX/FPR2 — RvD1, RvD2, MaR1), with direct MSU gout animal data (Zaninelli 2022 PMID 35716378; Jiang 2023 PMID 37996809; Zaninelli 2023 PMID 37651647); lactoferrin noted as fermentable adjunct. (5) Renamed CP6 from "Gasdermin D" to "Neutrophil Amplification + Pyroptotic Exit", split into CP6a (5-LOX → LTB4 → neutrophil chemotaxis — quercetin 300 nM IC50, AKBA ~2.7 μM cellular, EPA substrate competition, salidroside PMID 30265377) and CP6b (GSDMD pore formation — existing disulfiram/DMF/NSA); annotated aggNET resolution (Schauer 2014 PMID 24784231). Added two new wiki pages: complement-c5a-gout.md and spm-resolution-pathway.md. Updated ASCII diagram and GRAPH.md with new nodes (complement_c5a, s100a8a9, alx_fpr2_resolution, lt_b4_5lox) and edges.

April 2026 (v1.1): Added "AI Analysis Updates — Microbial Production Candidates" section synthesizing fermentation-scale NLRP3 inhibitor screening. Integrated findings on ursolic acid (8.59 g/L production record), quercetin (gout-validated, dual-mechanism), carnosine (unique hyperuricemia + inflammasome signature), taurine (native K⁺ efflux blockade), and kojic acid (flagged for immediate NLRP3 screening). Clarified potency gap vs. pharma benchmarks and multi-target stacking strategy. Cross-referenced [ai-analysis/07-nlrp3-inhibitor-screen.md].